a Mood Disorders Psychopharmacology Unit , University Health Network , Toronto , Canada.
b Department of Psychiatry , University of Toronto , Toronto , Canada.
Expert Rev Neurother. 2019 Apr;19(4):317-323. doi: 10.1080/14737175.2019.1580571. Epub 2019 Feb 20.
Depressive symptoms and episodes dominate the course of bipolar disorder. The morbidity of bipolar disorder is disproportionately mediated by depressive symptoms; economic costs of bipolar disorder are also disproportionately due to unremitting depressive symptoms. Relatively few treatment options have established unequivocal efficacy in the treatment of bipolar depression. Herein we review evidence regarding the efficacy of the D preferring D/D partial agonist cariprazine in the treatment of adults with bipolar depression. Areas covered: Randomized controlled trials that sought to determine the efficacy, tolerability, and safety of cariprazine in adults with bipolar I depression. Expert opinion: The available evidence from clinical trials indicates that cariprazine is effective at treating bipolar depression wherein treatment for bipolar depression remains an unmet need in bipolar disorder. Cariprazine has demonstrated good tolerability and safety profiles in bipolar disorder. Furthermore, cariprazine may be effective in improving both anhedonia and cognitive dysfunction. Long term prevention studies in bipolar depression, as well as separate studies evaluating efficacy in adults with bipolar II depression, are needed.
抑郁症状和发作主导双相情感障碍的病程。双相情感障碍的发病率不成比例地由抑郁症状介导；双相情感障碍的经济成本也不成比例地归因于持续不断的抑郁症状。相对较少的治疗选择在治疗双相抑郁方面具有明确的疗效。本文综述了 D 型优先 D/D 部分激动剂卡利拉嗪治疗成人双相抑郁的疗效证据。
旨在确定卡利拉嗪在治疗双相 I 型抑郁症成人中的疗效、耐受性和安全性的随机对照试验。
临床试验提供的证据表明，卡利拉嗪在治疗双相抑郁方面有效，而双相障碍中仍存在双相抑郁治疗的未满足需求。卡利拉嗪在双相障碍中表现出良好的耐受性和安全性。此外，卡利拉嗪可能在改善快感缺失和认知功能障碍方面有效。需要在双相抑郁中进行长期预防研究，以及在单独的研究中评估卡利拉嗪在双相 II 型抑郁症成人中的疗效。
